Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Okay. Great. I think we're going to get started here. I'm Terence Flynn, one of the biotech analysts at Goldman. And we're very pleased to have Magenta Therapeutics with us this afternoon. Joining us from the company is Jason Gardner, President and CEO.
Jason, thanks so much for being here with us this afternoon. Maybe just to start, given how new of a company you guys are, would just love a brief overview to kind of the formation of the company, the strategy and then why transplant. Like, why did you guys elect to focus there because it is somewhat novel in terms of the approach, and also taking this portfolio approach is somewhat different as well.
Well, first of all, Terence, thank you. Thank you for having me here and representing Magenta. It's a great pleasure. So we'll start at the end of that question, so why did we build Magenta, why transplant, why itâs this unique? So what we know is that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |